OncoC4 Reports Encouraging Phase 1/2 Data for Cesalatamig Monotherapy in Previously Treated Non-Small Cell Lung Cancer at SITC 2026
— 33% investigator-assessed objective response rate and 90% disease control rate at 10 mg/kg every three weeks in patients with PD-(L)1-resistant/refractory NSCLC — — Preliminary efficacy and safety results support further development of cesalatamig monotherapy — ROCKVILLE, Md., Nov. 6,...
Covered in this story
Call it yourself
No calls on $SITC yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Site Centers Corp →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.